14 September 2001
Ex-VivoHemoperfusion(eHPS)of Pig-Lungs with Whole Human Blood: Effectsof Complement Inhibitionwith a Soluble CI-Esterase-I nhibitor
H. Schelzig, F. Simon, C. Krischer, A. Vogel, D. AbendrothAnn Transplant 2001; 6(3): 34-39 :: ID: 497680
Abstract
Objectives: Xenotransplantation could be a future alternative to allotransplantation due to increasing organ shortage. Complement activation plays a major role in hyperacute rejection (HAR) in pig-to-human combinations. We developed an ex-vivo hemoperfusion (EHP) system to investigate pathophysiology of HARin the lung. After standardizing the model, the effect of a soluble complement inhibitor (C I-INH, Berinert'M) was investigated. Methods: Pig lungs were harvested following cold perfusion with Celsior'M preservation solution. EHP was performed using fresh heparinized human blood plus C I-INH (n=6) or heparinized human blood as control (n=4). Bloodgas analyses (BGA), pulmonalarterial pressure (PAP) were monitored. P-selectin and L-selectin were measured. Tissue samples were taken and microscopic changes evall!ated. Results: BGA, PAP, macroscopic and microscopic changes in the control group showed HAR, while the C I-INH group showed significantly longer function. Leucocytes and platelets were markedly activated in the control, wereas in the treated group L-selectin and P-selectin values indicated lower activation. HE stainings showed maintained lung architecture after perfusion of pig-lungs with human blood plus C I-INH. Immunohistochemistry showed less C Iq, C3, CSb-9 activation in the C I-INH group. Conclusions: Investigation of interaction of human blood with pig lung endothelium could be done in this model. C I-INH attenuates HAR in a pig-to-human lung transplantation model by decreasing the activation of adhesion molecules. C I-INH could playa role in induction therapy of future lung xenotransplantation.
Keywords: model, Xenotransplantation, complement inhibition
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






